MA46721A - Combinaison d'un vaccin à base de listeria avec des anticorps anti-ctla-4 ou anti-cd137 - Google Patents

Combinaison d'un vaccin à base de listeria avec des anticorps anti-ctla-4 ou anti-cd137

Info

Publication number
MA46721A
MA46721A MA046721A MA46721A MA46721A MA 46721 A MA46721 A MA 46721A MA 046721 A MA046721 A MA 046721A MA 46721 A MA46721 A MA 46721A MA 46721 A MA46721 A MA 46721A
Authority
MA
Morocco
Prior art keywords
ctla
listeria
antibodies
combination
based vaccine
Prior art date
Application number
MA046721A
Other languages
English (en)
Inventor
Sandra M Hayes
Rachelle Kosoff
Jun Zou
Original Assignee
Advaxis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advaxis Inc filed Critical Advaxis Inc
Publication of MA46721A publication Critical patent/MA46721A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MA046721A 2016-11-07 2017-11-07 Combinaison d'un vaccin à base de listeria avec des anticorps anti-ctla-4 ou anti-cd137 MA46721A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662418690P 2016-11-07 2016-11-07

Publications (1)

Publication Number Publication Date
MA46721A true MA46721A (fr) 2019-09-11

Family

ID=62076388

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046721A MA46721A (fr) 2016-11-07 2017-11-07 Combinaison d'un vaccin à base de listeria avec des anticorps anti-ctla-4 ou anti-cd137

Country Status (4)

Country Link
US (1) US20200061167A1 (fr)
EP (1) EP3534944A4 (fr)
MA (1) MA46721A (fr)
WO (1) WO2018085854A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
AU2015250111A1 (en) 2014-04-24 2016-12-08 Advaxis, Inc. Recombinant listeria vaccine strains and methods of producing the same
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
CA3035591A1 (fr) 2016-11-30 2018-06-07 Advaxis, Inc. Compositions immunogenes ciblant des mutations recurrentes du cancer et leurs procedes d'utilisation
CN111356760A (zh) 2017-09-19 2020-06-30 阿德瓦希斯公司 细菌或李斯特菌菌株的冻干组合物和方法
EP3730153A1 (fr) * 2019-04-26 2020-10-28 Medizinische Hochschule Hannover Immunothérapie personnalisée pour le traitement du cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1303299B1 (fr) * 2000-03-29 2010-07-28 The Trustees of The University of Pennsylvania Utilisation des peptides prokaryotic pest-like pour augmenter l'immunogénicité des antigènes
DE60232895D1 (de) * 2001-10-09 2009-08-20 Mayo Foundation Verwendung von agonistischen 4-1bb antikörpern zur erhöhung der immunantwort
US20120135033A1 (en) * 2008-05-19 2012-05-31 Anu Wallecha Multiple delivery system for heterologous antigens
WO2010042433A1 (fr) * 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combinaison d'anticorps cd137 et d'anticorps ctla-4 pour le traitement de maladies prolifératives
MA41217A (fr) * 2014-12-19 2017-10-24 Advaxis Inc Polythérapies ayant des souches de listeria recombinées

Also Published As

Publication number Publication date
EP3534944A4 (fr) 2020-07-01
EP3534944A1 (fr) 2019-09-11
WO2018085854A1 (fr) 2018-05-11
US20200061167A1 (en) 2020-02-27

Similar Documents

Publication Publication Date Title
MA41218A (fr) Combinaison de vaccin à base de listeria comportant des anticorps anti-ox40 ou anti-gitr
MA56006A (fr) Formulations sous-cutanées d'anticorps her2
EP3449940A4 (fr) Préparation contenant un anticorps
MA49043A (fr) Formulation stable d'anticorps
MA49726A (fr) Formulation d'anticorps anti-cgrp
MA42924A (fr) Variants optimisés d'anticorps anti-vegf
EP3618871A4 (fr) Formulations d'anticorps anti-lag3 etco-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1
EP3484518A4 (fr) Conjugués d'adjuvant d'anticorps
MA49033A (fr) Immunoconjugués d'un anticorps anti-pd-1 avec un il-2 mutant ou avec il-15
EP3609914A4 (fr) Lymphocytes t récepteurs d'antigènes chimériques ciblant le micro-environnement tumoral
MA49749A (fr) Anticorps anti-cd137
MA44238A (fr) Procédés d'augmentation de l'efficacité d'un vaccin par administration d'un antagoniste d'il-4r
EP3496753A4 (fr) Formulation d'anticorps anti-pd-1
MA44077A (fr) Anticorps neutralisants le virus de l'immunodéficience humaine
EP3668541A4 (fr) Formulations de vaccin pneumococcique conjugué
MA40682B1 (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
WO2018075692A3 (fr) Constructions d'anticorps
EP3362479A4 (fr) Agents de type anticorps spécifiques de l'antigène cd19 humain et leurs utilisations
MA44236A (fr) Anticorps anti-tgfbêta 2
MX2017003121A (es) Formulaciones de anticuerpos.
MA54139A (fr) Formulation d'anticorps
EP3735987A4 (fr) Conjugué d'anticorps à base d'amanitine
EP3391904A4 (fr) Composition pharmaceutique contenant un anticorps anti-récepteur de la tslp humaine
FR3022462B1 (fr) Composition orale d'anticorps anti-tnfalpha
EP3394099A4 (fr) Formulations d'anticorps anti-il-10 modifiés